TransCode Therapeutics board launches strategic review to maximize value of company and oncology portfolio

TransCode Therapeutics' board has initiated a formal strategic process to evaluate opportunities designed to maximize the value of the company and its oncology portfolio, including its lead product candidate TTX-MC138.

Detected & updated continuously · Source: Nebula